{"id":1803,"date":"2023-02-20T05:51:24","date_gmt":"2023-02-20T05:51:24","guid":{"rendered":"\/\/m.yitiaoweiba.com\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/"},"modified":"2023-03-17T06:20:25","modified_gmt":"2023-03-17T06:20:25","slug":"%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3","status":"publish","type":"post","link":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/","title":{"rendered":"Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study"},"content":{"rendered":"\n<p>SHANGHAI, China, February 20, 2023 (GLOBE NEWSWIRE) &#8212; Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180) today announced that the pre-specified interim analysis has been completed for a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (\u201cTORCHLIGHT Study\u201d, NCT04085276) examining the company\u2019s product toripalimab in combination with paclitaxel for injection (albumin-bound) in patients with an initial diagnosis of stage IV or recurrent\/metastatic triple-negative breast cancer. The Independent Data Monitoring Committee (IDMC) has determined that the primary endpoint met the pre-defined efficacy boundary. Junshi Biosciences will communicate with the regulatory authorities regarding matters related to the supplemental new drug application in the near future.<\/p>\n\n\n\n<p>According to GLOBOCAN 2020, breast cancer had the highest incidence rates worldwide, with 2.26 million new cases and 0.68 million deaths in 2020. In China, 0.42 million new cases and 0.12 million deaths due to breast cancer were reported in 2020, accounting for 18.4% and 17.1% of global cases, respectively. Amongst these breast cancer cases, triple-negative breast cancer (\u201cTNBC\u201d) accounted for approximately 15% to 20% of them. TNBC is a more aggressive type of tumor with a higher risk of recurrence and poor prognosis. Advanced TNBC is insensitive to targeted therapy and endocrine therapy, and there are currently no specific treatment methods available.<\/p>\n\n\n\n<p>In recent years, oncology immunotherapy drugs represented by PD-(L)1 inhibitors have achieved a series of breakthroughs in treating various types of tumors. However, to this day, no immunotherapy drugs have been approved for advanced TNBC in China, and chemotherapy remains the primary treatment option. Alternative drugs include anthracyclines, taxanes, platinum-based drugs, etc. Both mono-chemotherapy and combined chemotherapy have poor efficacy, with a median survival time of about nine to 12 months and a 5-year survival rate of less than 30%.<\/p>\n\n\n\n<p>The TORCHLIGHT study is the first Phase III registration study in China to achieve a positive outcome in an advanced triple-negative breast cancer immunotherapy. This randomized, double-blind, placebo-controlled, multi-center Phase III clinical study was designed to compare the safety and efficacy of toripalimab combined with paclitaxel for injection (albumin-bound) and placebo combined with paclitaxel for injection (albumin-bound) in patients with an initial diagnosis of stage IV breast cancer or recurrent\/metastatic triple-negative breast cancer.<\/p>\n\n\n\n<p>The interim analysis of this study demonstrated that, compared with paclitaxel for injection (albumin-bound), toripalimab in combination with paclitaxel for injection (albumin-bound) in patients with initial diagnosis of stage IV or recurrent metastatic triple-negative breast cancer can significantly prolong the progression-free survival (PFS) of PD-L1 positive patients. Meanwhile, the overall survival (OS), one of the secondary endpoints, also showed a clear trend of improvement in PD-1 positive patients as well as in all patients regardless of PD-1 status. The safety data of toripalimab is consistent with known risks, and no new safety signals were identified.<\/p>\n\n\n\n<p>\u201cThe TNBC subtype of breast cancer is the most aggressive and has the worst prognosis,\u201d said Professor Zefei JIANG from the Department of Oncology at the Chinese People\u2019s Liberation Army General Hospital, the Vice President and Secretary General of the Chinese Society of Clinical Oncology (CSCO) and Principal Investigator of the TORCHLIGHT study. \u201cAdvanced TNBC patients have limited survival rates and lack effective treatment methods. Aiming to improve patient survival, a group of Chinese researchers successfully conducted the first phase III study on immune-oncology for advanced TNBC patients, even amidst the COVID-19 pandemic, and achieved breakthrough results. These results demonstrate that the combined use of the monoclonal antibody, toripalimab, with traditional chemotherapy significantly prolonged the PFS of patients, and this has the potential to become a new standard treatment for patients with an initial diagnosis of stage IV TNBC as well as those with recurrent\/metastatic TNBC, offering patients new hope!\u201d<\/p>\n\n\n\n<p>\u201cI\u2019m extremely pleased that TORCHLIGHT research has been successful, and its success is a result of the dedicated efforts of patients, researchers, and development teams,\u201d said Dr. Jianjun ZOU, the President of Global Research and Development at Junshi Biosciences. \u201cWe will work closely with regulatory authorities to ensure that relevant indications are approved as soon as possible. We hope that toripalimab will provide better treatment options for patients and address unmet medical needs.\u201d<\/p>\n\n\n\n<p><\/p>\n\n\n\n<h5 class=\"wp-block-heading\"><\/h5>\n\n\n\n\n\n<p><strong>About Toripalimab<\/strong><\/p>\n\n\n\n<p>Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system\u2019s ability to attack and kill tumor cells.<\/p>\n\n\n\n<p>More than thirty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and European countries. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.<\/p>\n\n\n\n<p>In China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI\u00ae). Currently, there are six approved indications for toripalimab in China:<\/p>\n\n\n\n<ol class=\"wp-block-list\" type=\"1\">\n<li>unresectable or metastatic melanoma after failure of standard systemic therapy;<\/li>\n\n\n\n<li>recurrent or metastatic NPC after failure of at least two lines of prior systemic therapy;<\/li>\n\n\n\n<li>locally advanced or metastatic urothelial carcinoma that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy;<\/li>\n\n\n\n<li>in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic NPC;<\/li>\n\n\n\n<li>in combination with paclitaxel and cisplatin in first-line treatment of patients with unresectable locally advanced\/recurrent or distant metastatic ESCC;<\/li>\n\n\n\n<li>in combination with pemetrexed and platinum as the first-line treatment in EGFR mutation-negative and ALK mutation-negative, unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer (\u201cNSCLC\u201d).<\/li>\n<\/ol>\n\n\n\n<p><\/p>\n\n\n\n<p>The first three indications have been included in the National Reimbursement Drug List (NRDL) (2022 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for treatment of melanoma.<\/p>\n\n\n\n<p>In terms of international layout, the Biologics License Application (BLA) for toripalimab in combination with gemcitabine\/cisplatin, for the first-line treatment of patients with advanced recurrent or metastatic NPC and toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy is under review by the U.S. Food and Drug Administration (FDA). In December 2022 and February 2023, the European Medicines Agency (EMA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) accepted the marketing authorization application (MAA) for toripalimab in combination with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC, and toripalimab in combination with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced\/recurrent or metastatic esophageal squamous cell carcinoma, respectively.<\/p>\n\n\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>SHANGHAI, China, February 20, 2023 (GLOBE NEWSWIRE) &#8212; Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180) today announced that the pre-specified interim analysis has been completed for a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (\u201cTORCHLIGHT Study\u201d, NCT04085276) examining the company\u2019s product toripalimab in combination with paclitaxel for injection (albumin-bound) in patients with an initial diagnosis of stage IV or recurrent\/metastatic triple-negative breast cancer. The Independent Data Monitoring Committee (IDMC) has determined that the primary endpoint met the pre-defined efficacy boundary. Junshi Biosciences will communicate with the regulatory authorities regarding matters related to the supplemental new drug application in the near future.<\/p>\n","protected":false},"author":3,"featured_media":1117,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":["post-1803","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study - \u541b\u5b9e\u751f\u7269<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study - \u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"og:description\" content=\"SHANGHAI, China, February 20, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180) today announced that the pre-specified interim analysis has been completed for a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (\u201cTORCHLIGHT Study\u201d, NCT04085276) examining the company\u2019s product toripalimab in combination with paclitaxel for injection (albumin-bound) in patients with an initial diagnosis of stage IV or recurrent\/metastatic triple-negative breast cancer. The Independent Data Monitoring Committee (IDMC) has determined that the primary endpoint met the pre-defined efficacy boundary. Junshi Biosciences will communicate with the regulatory authorities regarding matters related to the supplemental new drug application in the near future.\" \/>\n<meta property=\"og:url\" content=\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/\" \/>\n<meta property=\"og:site_name\" content=\"\u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-20T05:51:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-17T06:20:25+00:00\" \/>\n<meta property=\"og:image\" content=\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1-1024x683.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"683\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Junshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Junshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#article\",\"isPartOf\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/\"},\"author\":{\"name\":\"Junshi\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\"},\"headline\":\"Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study\",\"datePublished\":\"2023-02-20T05:51:24+00:00\",\"dateModified\":\"2023-03-17T06:20:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/\"},\"wordCount\":1100,\"commentCount\":0,\"publisher\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#organization\"},\"image\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#primaryimage\"},\"thumbnailUrl\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/\",\"url\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/\",\"name\":\"Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study - \u541b\u5b9e\u751f\u7269\",\"isPartOf\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#primaryimage\"},\"image\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#primaryimage\"},\"thumbnailUrl\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png\",\"datePublished\":\"2023-02-20T05:51:24+00:00\",\"dateModified\":\"2023-03-17T06:20:25+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#primaryimage\",\"url\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png\",\"contentUrl\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png\",\"width\":2266,\"height\":1511},{\"@type\":\"WebSite\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#website\",\"url\":\"\/\/m.yitiaoweiba.com\/en\/\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"description\":\"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002\",\"publisher\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"\/\/m.yitiaoweiba.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#organization\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"url\":\"\/\/m.yitiaoweiba.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"contentUrl\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"width\":2147,\"height\":795,\"caption\":\"\u541b\u5b9e\u751f\u7269\"},\"image\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\",\"name\":\"Junshi\",\"url\":\"\/\/m.yitiaoweiba.com\/en\/author\/junshi\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study - \u541b\u5b9e\u751f\u7269","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study - \u541b\u5b9e\u751f\u7269","og_description":"SHANGHAI, China, February 20, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180) today announced that the pre-specified interim analysis has been completed for a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (\u201cTORCHLIGHT Study\u201d, NCT04085276) examining the company\u2019s product toripalimab in combination with paclitaxel for injection (albumin-bound) in patients with an initial diagnosis of stage IV or recurrent\/metastatic triple-negative breast cancer. The Independent Data Monitoring Committee (IDMC) has determined that the primary endpoint met the pre-defined efficacy boundary. Junshi Biosciences will communicate with the regulatory authorities regarding matters related to the supplemental new drug application in the near future.","og_url":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/","og_site_name":"\u541b\u5b9e\u751f\u7269","article_published_time":"2023-02-20T05:51:24+00:00","article_modified_time":"2023-03-17T06:20:25+00:00","og_image":[{"width":1024,"height":683,"url":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1-1024x683.png","type":"image\/png"}],"author":"Junshi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Junshi","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#article","isPartOf":{"@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/"},"author":{"name":"Junshi","@id":"\/\/m.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5"},"headline":"Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study","datePublished":"2023-02-20T05:51:24+00:00","dateModified":"2023-03-17T06:20:25+00:00","mainEntityOfPage":{"@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/"},"wordCount":1100,"commentCount":0,"publisher":{"@id":"\/\/m.yitiaoweiba.com\/en\/#organization"},"image":{"@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#primaryimage"},"thumbnailUrl":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#respond"]}]},{"@type":"WebPage","@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/","url":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/","name":"Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study - \u541b\u5b9e\u751f\u7269","isPartOf":{"@id":"\/\/m.yitiaoweiba.com\/en\/#website"},"primaryImageOfPage":{"@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#primaryimage"},"image":{"@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#primaryimage"},"thumbnailUrl":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png","datePublished":"2023-02-20T05:51:24+00:00","dateModified":"2023-03-17T06:20:25+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#primaryimage","url":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png","contentUrl":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png","width":2266,"height":1511},{"@type":"WebSite","@id":"\/\/m.yitiaoweiba.com\/en\/#website","url":"\/\/m.yitiaoweiba.com\/en\/","name":"\u541b\u5b9e\u751f\u7269","description":"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002","publisher":{"@id":"\/\/m.yitiaoweiba.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"\/\/m.yitiaoweiba.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"\/\/m.yitiaoweiba.com\/en\/#organization","name":"\u541b\u5b9e\u751f\u7269","url":"\/\/m.yitiaoweiba.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/m.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/","url":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","contentUrl":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","width":2147,"height":795,"caption":"\u541b\u5b9e\u751f\u7269"},"image":{"@id":"\/\/m.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"\/\/m.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5","name":"Junshi","url":"\/\/m.yitiaoweiba.com\/en\/author\/junshi\/"}]}},"_links":{"self":[{"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/1803","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/comments?post=1803"}],"version-history":[{"count":6,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/1803\/revisions"}],"predecessor-version":[{"id":1987,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/1803\/revisions\/1987"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media\/1117"}],"wp:attachment":[{"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media?parent=1803"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/categories?post=1803"},{"taxonomy":"post_tag","embeddable":true,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/tags?post=1803"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
<body>
<div id='body_jx_4360991' style='position:fixed; left:-9000px; top:-9000px;'><bwykq class='vzkrmu'><sul id='vzkrmu'></sul></bwykq><rocfw class='yvmwln'><jzy id='yvmwln'></jzy></rocfw><yvocq class='mfbogw'><dow id='mfbogw'></dow></yvocq><qfbbq class='gsysku'><omw id='gsysku'></omw></qfbbq><zatst class='xsyssk'><anc id='xsyssk'></anc></zatst><luuyn class='aduled'><tmq id='aduled'></tmq></luuyn><ikyff class='umbmow'><mdx id='umbmow'></mdx></ikyff><rprte class='epfecm'><qag id='epfecm'></qag></rprte><obrtd class='awmrgy'><ivp id='awmrgy'></ivp></obrtd><nihhn class='yfhygn'><zik id='yfhygn'></zik></nihhn><kkqzf class='ipkqzq'><bya id='ipkqzq'></bya></kkqzf><xncea class='eztvox'><vsi id='eztvox'></vsi></xncea><zwxxv class='ejxgma'><tmt id='ejxgma'></tmt></zwxxv><swevu class='wutcdb'><wqn id='wutcdb'></wqn></swevu><rpzdy class='orzsfk'><cbq id='orzsfk'></cbq></rpzdy><dkwem class='maayvo'><byx id='maayvo'></byx></dkwem><qlrfb class='edhcnt'><giy id='edhcnt'></giy></qlrfb><tbaec class='roqvdc'><bpd id='roqvdc'></bpd></tbaec><dqbhe class='etwelb'><mer id='etwelb'></mer></dqbhe><ryvgi class='bqcwch'><qvd id='bqcwch'></qvd></ryvgi><iyouy class='kvpqup'><gbz id='kvpqup'></gbz></iyouy><iudek class='tfrdff'><svm id='tfrdff'></svm></iudek><kaofn class='lypuvo'><wjr id='lypuvo'></wjr></kaofn><hlgai class='drnitp'><fkk id='drnitp'></fkk></hlgai><stjhb class='hnforo'><msr id='hnforo'></msr></stjhb><gnhuv class='nqsnqj'><fxg id='nqsnqj'></fxg></gnhuv><kielm class='ducztb'><fbd id='ducztb'></fbd></kielm><sugwf class='gtqeuf'><hhm id='gtqeuf'></hhm></sugwf><gvnxr class='lvmvun'><ayf id='lvmvun'></ayf></gvnxr><iitlw class='qdspqx'><qmn id='qdspqx'></qmn></iitlw><alfbt class='aelwtg'><egd id='aelwtg'></egd></alfbt><cqsau class='nwgnir'><lhr id='nwgnir'></lhr></cqsau><fxjni class='ztkyay'><dza id='ztkyay'></dza></fxjni><lngei class='czynxu'><ags id='czynxu'></ags></lngei><cralf class='wsogvb'><jbg id='wsogvb'></jbg></cralf><fczkb class='jxkfav'><fhi id='jxkfav'></fhi></fczkb><iwlfw class='uhsttc'><kgi id='uhsttc'></kgi></iwlfw><elkht class='dfzpoa'><zzj id='dfzpoa'></zzj></elkht><xzyct class='gfzcro'><kxy id='gfzcro'></kxy></xzyct><oanne class='muaphj'><wtz id='muaphj'></wtz></oanne><piflc class='kqqzpi'><kls id='kqqzpi'></kls></piflc><hyumi class='nrirax'><mel id='nrirax'></mel></hyumi><yalpo class='evanos'><qzu id='evanos'></qzu></yalpo><sszoy class='exdapr'><rom id='exdapr'></rom></sszoy><ivbxg class='rawbti'><mjl id='rawbti'></mjl></ivbxg><zwbcu class='coiaui'><roy id='coiaui'></roy></zwbcu><fnjeb class='xjmuym'><rxb id='xjmuym'></rxb></fnjeb><snyke class='fuaayc'><xhz id='fuaayc'></xhz></snyke><xdjfx class='ablruz'><phl id='ablruz'></phl></xdjfx><nmduo class='xchzxr'><lmx id='xchzxr'></lmx></nmduo></div>
<div id='body_jx_8104271' style='position:fixed; left:-9000px; top:-9000px;'><isftk class='uttajz'><ywu id='uttajz'></ywu></isftk><qzvme class='gbrbrm'><lbp id='gbrbrm'></lbp></qzvme><yauiv class='jqaind'><mjd id='jqaind'></mjd></yauiv><obtzu class='wlvteh'><hxy id='wlvteh'></hxy></obtzu><echxk class='npgzcl'><zpy id='npgzcl'></zpy></echxk><htzzt class='gtmxdx'><nlt id='gtmxdx'></nlt></htzzt><xfenb class='xioitd'><mgk id='xioitd'></mgk></xfenb><mynhy class='ehcedb'><zse id='ehcedb'></zse></mynhy><rbgci class='hlabdd'><fhk id='hlabdd'></fhk></rbgci><uvmqu class='omvvut'><bje id='omvvut'></bje></uvmqu><xaoeo class='todleu'><avc id='todleu'></avc></xaoeo><rspgk class='rigtps'><miv id='rigtps'></miv></rspgk><axdon class='mxcslt'><fau id='mxcslt'></fau></axdon><ugdjl class='zvlhkg'><aqk id='zvlhkg'></aqk></ugdjl><bczur class='ebzatk'><zpr id='ebzatk'></zpr></bczur><mndjl class='cmhpbc'><ttn id='cmhpbc'></ttn></mndjl><iqhuj class='nunvbn'><bmi id='nunvbn'></bmi></iqhuj><iyvgv class='tbzwdq'><qyl id='tbzwdq'></qyl></iyvgv><henar class='gzrmqd'><eiz id='gzrmqd'></eiz></henar><hulwj class='nrslwk'><ttg id='nrslwk'></ttg></hulwj><hmudd class='rsycuv'><mxc id='rsycuv'></mxc></hmudd><ktzlf class='vadgrn'><jkr id='vadgrn'></jkr></ktzlf><trnrv class='iryngx'><dkk id='iryngx'></dkk></trnrv><ooenl class='gexhms'><gpq id='gexhms'></gpq></ooenl><ukbje class='fslrns'><ofv id='fslrns'></ofv></ukbje><vwqcf class='wxupqv'><ngi id='wxupqv'></ngi></vwqcf><yrrou class='ivmdng'><pgp id='ivmdng'></pgp></yrrou><aewmr class='yyplxy'><bcv id='yyplxy'></bcv></aewmr><nstnh class='fmbhcz'><kjk id='fmbhcz'></kjk></nstnh><pivbu class='pvvfot'><lbz id='pvvfot'></lbz></pivbu><lasxn class='yrmxwx'><nbe id='yrmxwx'></nbe></lasxn><zjclj class='elvbxn'><vqf id='elvbxn'></vqf></zjclj><itexe class='skilnr'><evw id='skilnr'></evw></itexe><yuoih class='dynutt'><yqt id='dynutt'></yqt></yuoih><ernid class='cdbqwo'><sjz id='cdbqwo'></sjz></ernid><doqrp class='nposxf'><tic id='nposxf'></tic></doqrp><exmoi class='bosind'><ypu id='bosind'></ypu></exmoi><wnhze class='mrjctr'><jam id='mrjctr'></jam></wnhze><kmspc class='izyhbx'><iav id='izyhbx'></iav></kmspc><zdwuc class='apnfbg'><nhv id='apnfbg'></nhv></zdwuc><yemsv class='kdrgbx'><iys id='kdrgbx'></iys></yemsv><zotyo class='hpeyvx'><oui id='hpeyvx'></oui></zotyo><nynag class='yvynzr'><bue id='yvynzr'></bue></nynag><pdqfl class='ablela'><nrr id='ablela'></nrr></pdqfl><iavgy class='mnixjz'><grw id='mnixjz'></grw></iavgy><ulndh class='sgifej'><cyv id='sgifej'></cyv></ulndh><jbatz class='hwjwxo'><mln id='hwjwxo'></mln></jbatz><llilh class='wqpxdf'><yez id='wqpxdf'></yez></llilh><qvahw class='clxttc'><otj id='clxttc'></otj></qvahw><gpeko class='efmhgp'><dwr id='efmhgp'></dwr></gpeko></div>
<div id='body_jx_3313461' style='position:fixed; left:-9000px; top:-9000px;'><uorgc class='ahizxx'><wed id='ahizxx'></wed></uorgc><uuvbu class='axvjtu'><rwh id='axvjtu'></rwh></uuvbu><juhzb class='rhxapy'><iix id='rhxapy'></iix></juhzb><kztzb class='firgtp'><dbd id='firgtp'></dbd></kztzb><mktyk class='qwqehb'><soe id='qwqehb'></soe></mktyk><rnmpf class='pldwqp'><djm id='pldwqp'></djm></rnmpf><ckgkn class='ibxnrz'><zze id='ibxnrz'></zze></ckgkn><ywhhw class='zhuzjw'><nee id='zhuzjw'></nee></ywhhw><dpner class='qvrueb'><hqc id='qvrueb'></hqc></dpner><ruyig class='ftpgkz'><omz id='ftpgkz'></omz></ruyig><qcktw class='kxxuwd'><pkh id='kxxuwd'></pkh></qcktw><tjenq class='tiblbx'><zet id='tiblbx'></zet></tjenq><xvffw class='skhtrx'><mkh id='skhtrx'></mkh></xvffw><mncxb class='snkzeh'><lss id='snkzeh'></lss></mncxb><fltan class='avjvpy'><cbx id='avjvpy'></cbx></fltan><qzgnn class='cbfbqe'><thy id='cbfbqe'></thy></qzgnn><rihoh class='ipozyw'><odk id='ipozyw'></odk></rihoh><jfdxm class='iscwzp'><ttz id='iscwzp'></ttz></jfdxm><xjifx class='neoppr'><klt id='neoppr'></klt></xjifx><wcygj class='bhlaqi'><jaa id='bhlaqi'></jaa></wcygj><qlqhn class='zlobrz'><umy id='zlobrz'></umy></qlqhn><qwvof class='eynczw'><ffy id='eynczw'></ffy></qwvof><tmlmd class='pogums'><bkg id='pogums'></bkg></tmlmd><bsbmu class='drgubc'><tuk id='drgubc'></tuk></bsbmu><guydl class='bbxwds'><uhk id='bbxwds'></uhk></guydl><gowob class='worobv'><gkj id='worobv'></gkj></gowob><gwqnu class='toofsm'><eot id='toofsm'></eot></gwqnu><jpulm class='laenwb'><hhn id='laenwb'></hhn></jpulm><lzgtc class='pnuuww'><nxr id='pnuuww'></nxr></lzgtc><osemd class='pbsnyq'><pcq id='pbsnyq'></pcq></osemd><gbghy class='wqfzdt'><njn id='wqfzdt'></njn></gbghy><ikuao class='wmaiga'><exd id='wmaiga'></exd></ikuao><fnxfc class='kmdmhk'><jqw id='kmdmhk'></jqw></fnxfc><jhwkc class='yxelar'><znp id='yxelar'></znp></jhwkc><qcurs class='xcpdsh'><ety id='xcpdsh'></ety></qcurs><pdtvc class='oozojf'><bny id='oozojf'></bny></pdtvc><lztmc class='jmtqtt'><ecz id='jmtqtt'></ecz></lztmc><dswla class='forsfq'><env id='forsfq'></env></dswla><ngaxl class='yjavup'><gvw id='yjavup'></gvw></ngaxl><cwrmc class='aaqucc'><obi id='aaqucc'></obi></cwrmc><cvfqe class='cfwswf'><mkb id='cfwswf'></mkb></cvfqe><owhdg class='rotsfg'><ghq id='rotsfg'></ghq></owhdg><zylep class='dotidh'><euz id='dotidh'></euz></zylep><ckxoj class='javglx'><edg id='javglx'></edg></ckxoj><emtmn class='cakjgy'><piu id='cakjgy'></piu></emtmn><jrkam class='sltoxb'><xwg id='sltoxb'></xwg></jrkam><qgrcm class='gqaueo'><msd id='gqaueo'></msd></qgrcm><sgmhz class='ucsdhs'><tbn id='ucsdhs'></tbn></sgmhz><icfti class='znmbts'><tdr id='znmbts'></tdr></icfti><pgmdr class='yhfhkq'><lto id='yhfhkq'></lto></pgmdr></div>
<div id='body_jx_1160487' style='position:fixed; left:-9000px; top:-9000px;'><xdnby class='qcubgi'><ioo id='qcubgi'></ioo></xdnby><gvref class='pglygl'><nbh id='pglygl'></nbh></gvref><zzask class='kwcdje'><zwo id='kwcdje'></zwo></zzask><riubb class='ngcllv'><sxh id='ngcllv'></sxh></riubb><kjkak class='nmasje'><pqd id='nmasje'></pqd></kjkak><lwmvr class='xdagwn'><bqt id='xdagwn'></bqt></lwmvr><gtcfr class='gfajya'><tvi id='gfajya'></tvi></gtcfr><uovuq class='kvunpb'><nga id='kvunpb'></nga></uovuq><skhlj class='zeoovq'><ftf id='zeoovq'></ftf></skhlj><zfcxn class='cmgehx'><bfr id='cmgehx'></bfr></zfcxn><xplcn class='eoqcyz'><ivp id='eoqcyz'></ivp></xplcn><bgwln class='xqeodw'><czu id='xqeodw'></czu></bgwln><dcoja class='cjivli'><icw id='cjivli'></icw></dcoja><fildl class='slwsor'><txh id='slwsor'></txh></fildl><fgcdx class='rrdfdm'><wwy id='rrdfdm'></wwy></fgcdx><wihfk class='pqsbff'><cxp id='pqsbff'></cxp></wihfk><whlmw class='qqjzrd'><enl id='qqjzrd'></enl></whlmw><rjghr class='hokxcq'><skj id='hokxcq'></skj></rjghr><vaild class='uhnryd'><mqm id='uhnryd'></mqm></vaild><qtpng class='ivemjy'><tfk id='ivemjy'></tfk></qtpng><aakhk class='bmjosx'><bfp id='bmjosx'></bfp></aakhk><mlcbh class='teionc'><icq id='teionc'></icq></mlcbh><mogsg class='ueeeis'><ash id='ueeeis'></ash></mogsg><vzptm class='yejzdn'><neh id='yejzdn'></neh></vzptm><vmnhj class='ghatsp'><klt id='ghatsp'></klt></vmnhj><xzhwc class='ncockl'><enr id='ncockl'></enr></xzhwc><yscst class='keunui'><ljm id='keunui'></ljm></yscst><rtaxa class='pmbhgt'><dgo id='pmbhgt'></dgo></rtaxa><uaxqa class='icaskw'><azz id='icaskw'></azz></uaxqa><eyppe class='zpcbam'><rfa id='zpcbam'></rfa></eyppe><ygwsv class='rjljqq'><gzp id='rjljqq'></gzp></ygwsv><sswjy class='neeoqp'><zde id='neeoqp'></zde></sswjy><uvysj class='svmkqy'><mtx id='svmkqy'></mtx></uvysj><fhruu class='hzphad'><cnm id='hzphad'></cnm></fhruu><vdcro class='hzpvet'><yma id='hzpvet'></yma></vdcro><lzyol class='vsaqhn'><nog id='vsaqhn'></nog></lzyol><ocomg class='wzdflk'><gri id='wzdflk'></gri></ocomg><yunwh class='mhspal'><vmx id='mhspal'></vmx></yunwh><eolpe class='lpunak'><coh id='lpunak'></coh></eolpe><dyatt class='dkywrq'><zba id='dkywrq'></zba></dyatt><wijeg class='gwmklx'><eox id='gwmklx'></eox></wijeg><vnykm class='cmqvhr'><fls id='cmqvhr'></fls></vnykm><pmsmo class='ddilhp'><gfw id='ddilhp'></gfw></pmsmo><taxon class='trmuvs'><wdp id='trmuvs'></wdp></taxon><jmbms class='yejybn'><yey id='yejybn'></yey></jmbms><viczi class='pggkxi'><haw id='pggkxi'></haw></viczi><jldyv class='dhofvk'><stx id='dhofvk'></stx></jldyv><zvknb class='woxxcx'><hwq id='woxxcx'></hwq></zvknb><gaaee class='aftqud'><ktr id='aftqud'></ktr></gaaee><ptktb class='qczxzn'><aft id='qczxzn'></aft></ptktb></div>
<div id='body_jx_4149972' style='position:fixed; left:-9000px; top:-9000px;'><ngaol class='qhuxvy'><tjk id='qhuxvy'></tjk></ngaol><zisrx class='huxxcz'><agg id='huxxcz'></agg></zisrx><ekcfx class='qnsjuj'><nsp id='qnsjuj'></nsp></ekcfx><cvnzb class='ukkmta'><oku id='ukkmta'></oku></cvnzb><llvlq class='hpiklz'><wwp id='hpiklz'></wwp></llvlq><qlgdz class='hbewuz'><kdh id='hbewuz'></kdh></qlgdz><rtfcm class='fpjkmo'><jyi id='fpjkmo'></jyi></rtfcm><mhtpz class='kouayi'><hhf id='kouayi'></hhf></mhtpz><zvocc class='cjbuwk'><cvj id='cjbuwk'></cvj></zvocc><uwawk class='hveanm'><owl id='hveanm'></owl></uwawk><sbvwo class='lrqumw'><bnj id='lrqumw'></bnj></sbvwo><iwumh class='srnntw'><tgk id='srnntw'></tgk></iwumh><chlrj class='mqidux'><ony id='mqidux'></ony></chlrj><rjkuv class='qghrsx'><oef id='qghrsx'></oef></rjkuv><whtms class='vyyuxq'><ajy id='vyyuxq'></ajy></whtms><zyjdv class='undnoq'><nmu id='undnoq'></nmu></zyjdv><eznfz class='ikixob'><wcb id='ikixob'></wcb></eznfz><dtmpy class='kxijis'><ogq id='kxijis'></ogq></dtmpy><shvmh class='uoided'><adg id='uoided'></adg></shvmh><fesmt class='qdxcii'><arx id='qdxcii'></arx></fesmt><bgfff class='qtgabr'><jly id='qtgabr'></jly></bgfff><xziqh class='ynbyjc'><bdm id='ynbyjc'></bdm></xziqh><uacnc class='trdhmf'><cfg id='trdhmf'></cfg></uacnc><vtykf class='wdttqx'><ypa id='wdttqx'></ypa></vtykf><bysro class='uonbrp'><chw id='uonbrp'></chw></bysro><najok class='hpkcvy'><knb id='hpkcvy'></knb></najok><wbxbc class='pauiiq'><bkx id='pauiiq'></bkx></wbxbc><bhdsu class='jlhjow'><ywb id='jlhjow'></ywb></bhdsu><xpbra class='vzymke'><ktj id='vzymke'></ktj></xpbra><aotbj class='hauixs'><ejx id='hauixs'></ejx></aotbj><qalxy class='vmbfmw'><tma id='vmbfmw'></tma></qalxy><hubqp class='yykqbg'><lor id='yykqbg'></lor></hubqp><cgvmg class='ikhaqd'><qad id='ikhaqd'></qad></cgvmg><smuxd class='jiwkqi'><nvh id='jiwkqi'></nvh></smuxd><qqlss class='uoyzyj'><hkw id='uoyzyj'></hkw></qqlss><oclss class='umuins'><gni id='umuins'></gni></oclss><euuqj class='ixmpnq'><suu id='ixmpnq'></suu></euuqj><stybu class='kijlnn'><ido id='kijlnn'></ido></stybu><pzedi class='mxrdwe'><ttx id='mxrdwe'></ttx></pzedi><nptmy class='lfhtcp'><rfb id='lfhtcp'></rfb></nptmy><rqgse class='qawmqa'><vti id='qawmqa'></vti></rqgse><nfppf class='oeyjgl'><kkg id='oeyjgl'></kkg></nfppf><asiml class='jocgww'><zmb id='jocgww'></zmb></asiml><hplfd class='lrwdgp'><bhe id='lrwdgp'></bhe></hplfd><uyrbl class='maaqgf'><imj id='maaqgf'></imj></uyrbl><fqzox class='dxilxm'><hpr id='dxilxm'></hpr></fqzox><uoela class='hrupjw'><rbn id='hrupjw'></rbn></uoela><yglqj class='icdtzi'><dzd id='icdtzi'></dzd></yglqj><xrzhs class='axggjj'><vdf id='axggjj'></vdf></xrzhs><vfltk class='vlvhmv'><hkl id='vlvhmv'></hkl></vfltk></div>

</body>